|
US4232027A
(en)
|
1979-01-29 |
1980-11-04 |
E. R. Squibb & Sons, Inc. |
1,2-Dihydro-2-oxo-4-phenyl-3-quinolinecarbonitrile derivatives
|
|
DE3381783D1
(de)
|
1982-03-03 |
1990-09-13 |
Genentech Inc |
Menschliches antithrombin iii, dns sequenzen dafuer, expressions- und klonierungsvektoren die solche sequenzen enthalten und damit transformierte zellkulturen, verfahren zur expression von menschlichem antithrombin iii und diese enthaltende pharmazeutische zusammensetzungen.
|
|
GB8827305D0
(en)
|
1988-11-23 |
1988-12-29 |
British Bio Technology |
Compounds
|
|
JP2762522B2
(ja)
|
1989-03-06 |
1998-06-04 |
藤沢薬品工業株式会社 |
血管新生阻害剤
|
|
US5112946A
(en)
|
1989-07-06 |
1992-05-12 |
Repligen Corporation |
Modified pf4 compositions and methods of use
|
|
PT98990A
(pt)
|
1990-09-19 |
1992-08-31 |
American Home Prod |
Processo para a preparacao de esteres de acidos carboxilicos de rapamicina
|
|
US5892112A
(en)
|
1990-11-21 |
1999-04-06 |
Glycomed Incorporated |
Process for preparing synthetic matrix metalloprotease inhibitors
|
|
US5120842A
(en)
|
1991-04-01 |
1992-06-09 |
American Home Products Corporation |
Silyl ethers of rapamycin
|
|
US5100883A
(en)
|
1991-04-08 |
1992-03-31 |
American Home Products Corporation |
Fluorinated esters of rapamycin
|
|
US5118678A
(en)
|
1991-04-17 |
1992-06-02 |
American Home Products Corporation |
Carbamates of rapamycin
|
|
AU658646B2
(en)
|
1991-05-10 |
1995-04-27 |
Rhone-Poulenc Rorer International (Holdings) Inc. |
Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
|
|
US5118677A
(en)
|
1991-05-20 |
1992-06-02 |
American Home Products Corporation |
Amide esters of rapamycin
|
|
NZ243082A
(en)
|
1991-06-28 |
1995-02-24 |
Ici Plc |
4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
|
|
US5151413A
(en)
|
1991-11-06 |
1992-09-29 |
American Home Products Corporation |
Rapamycin acetals as immunosuppressant and antifungal agents
|
|
GB9125660D0
(en)
|
1991-12-03 |
1992-01-29 |
Smithkline Beecham Plc |
Novel compound
|
|
GB9300059D0
(en)
|
1992-01-20 |
1993-03-03 |
Zeneca Ltd |
Quinazoline derivatives
|
|
US5521184A
(en)
|
1992-04-03 |
1996-05-28 |
Ciba-Geigy Corporation |
Pyrimidine derivatives and processes for the preparation thereof
|
|
ZA935112B
(en)
|
1992-07-17 |
1994-02-08 |
Smithkline Beecham Corp |
Rapamycin derivatives
|
|
ZA935111B
(en)
|
1992-07-17 |
1994-02-04 |
Smithkline Beecham Corp |
Rapamycin derivatives
|
|
US5256790A
(en)
|
1992-08-13 |
1993-10-26 |
American Home Products Corporation |
27-hydroxyrapamycin and derivatives thereof
|
|
GB9221220D0
(en)
|
1992-10-09 |
1992-11-25 |
Sandoz Ag |
Organic componds
|
|
US5258389A
(en)
|
1992-11-09 |
1993-11-02 |
Merck & Co., Inc. |
O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives
|
|
DE69334100T2
(de)
|
1992-11-13 |
2007-07-19 |
Immunex Corp., Seattle |
Elk ligand, ein cytokin
|
|
US5455258A
(en)
|
1993-01-06 |
1995-10-03 |
Ciba-Geigy Corporation |
Arylsulfonamido-substituted hydroxamic acids
|
|
US5629327A
(en)
|
1993-03-01 |
1997-05-13 |
Childrens Hospital Medical Center Corp. |
Methods and compositions for inhibition of angiogenesis
|
|
US5516658A
(en)
|
1993-08-20 |
1996-05-14 |
Immunex Corporation |
DNA encoding cytokines that bind the cell surface receptor hek
|
|
WO1995009847A1
(en)
|
1993-10-01 |
1995-04-13 |
Ciba-Geigy Ag |
Pyrimidineamine derivatives and processes for the preparation thereof
|
|
US5656643A
(en)
|
1993-11-08 |
1997-08-12 |
Rhone-Poulenc Rorer Pharmaceuticals Inc. |
Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
|
|
JP4105761B2
(ja)
|
1993-11-19 |
2008-06-25 |
アボット・ラボラトリーズ |
ラパミシン（マクロライド）の半合成類似体免疫調節剤
|
|
SG64372A1
(en)
|
1993-12-17 |
1999-04-27 |
Novartis Ag |
Rapamycin derivatives
|
|
US5700823A
(en)
|
1994-01-07 |
1997-12-23 |
Sugen, Inc. |
Treatment of platelet derived growth factor related disorders such as cancers
|
|
IL112249A
(en)
|
1994-01-25 |
2001-11-25 |
Warner Lambert Co |
Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
|
|
IL112248A0
(en)
|
1994-01-25 |
1995-03-30 |
Warner Lambert Co |
Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
|
|
WO1995024190A2
(en)
|
1994-03-07 |
1995-09-14 |
Sugen, Inc. |
Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof
|
|
CA2189028A1
(en)
|
1994-04-15 |
1995-10-26 |
Gary M. Fox |
Hek5, hek7, hek8, hek11, new eph-like receptor protein tyrosine kinases
|
|
DK0682027T3
(da)
|
1994-05-03 |
1998-05-04 |
Ciba Geigy Ag |
Pyrrolopyrimidinderivater med antiproliferativ virkning
|
|
US6303769B1
(en)
|
1994-07-08 |
2001-10-16 |
Immunex Corporation |
Lerk-5 dna
|
|
US5919905A
(en)
|
1994-10-05 |
1999-07-06 |
Immunex Corporation |
Cytokine designated LERK-6
|
|
US6057124A
(en)
|
1995-01-27 |
2000-05-02 |
Amgen Inc. |
Nucleic acids encoding ligands for HEK4 receptors
|
|
US5863949A
(en)
|
1995-03-08 |
1999-01-26 |
Pfizer Inc |
Arylsulfonylamino hydroxamic acid derivatives
|
|
DE69536015D1
(de)
|
1995-03-30 |
2009-12-10 |
Pfizer Prod Inc |
Chinazolinone Derivate
|
|
AU711592B2
(en)
|
1995-04-03 |
1999-10-14 |
Novartis Ag |
Pyrazole derivatives and processes for the preparation thereof
|
|
CA2218503C
(en)
|
1995-04-20 |
2001-07-24 |
Pfizer Inc. |
Arylsulfonyl hydroxamic acid derivatives
|
|
GB9508538D0
(en)
|
1995-04-27 |
1995-06-14 |
Zeneca Ltd |
Quinazoline derivatives
|
|
US5747498A
(en)
|
1996-05-28 |
1998-05-05 |
Pfizer Inc. |
Alkynyl and azido-substituted 4-anilinoquinazolines
|
|
US5880141A
(en)
|
1995-06-07 |
1999-03-09 |
Sugen, Inc. |
Benzylidene-Z-indoline compounds for the treatment of disease
|
|
US5650415A
(en)
|
1995-06-07 |
1997-07-22 |
Sugen, Inc. |
Quinoline compounds
|
|
AU712193B2
(en)
|
1995-06-09 |
1999-10-28 |
Novartis Ag |
Rapamycin derivatives
|
|
DK0836605T3
(da)
|
1995-07-06 |
2002-05-13 |
Novartis Ag |
Pyrrolopyrimidiner og fremgangsmåder til deres fremstilling
|
|
DE19534177A1
(de)
|
1995-09-15 |
1997-03-20 |
Merck Patent Gmbh |
Cyclische Adhäsionsinhibitoren
|
|
AR004010A1
(es)
|
1995-10-11 |
1998-09-30 |
Glaxo Group Ltd |
Compuestos heterociclicos
|
|
GB9523675D0
(en)
|
1995-11-20 |
1996-01-24 |
Celltech Therapeutics Ltd |
Chemical compounds
|
|
EP0780386B1
(en)
|
1995-12-20 |
2002-10-02 |
F. Hoffmann-La Roche Ag |
Matrix metalloprotease inhibitors
|
|
JP4275733B2
(ja)
|
1996-01-23 |
2009-06-10 |
ノバルティス アクチエンゲゼルシャフト |
ピロロピリミジンおよびその製造法
|
|
JP3406763B2
(ja)
|
1996-01-30 |
2003-05-12 |
東レ・ダウコーニング・シリコーン株式会社 |
シリコーンゴム組成物
|
|
GB9603097D0
(en)
|
1996-02-14 |
1996-04-10 |
Zeneca Ltd |
Quinazoline compounds
|
|
GB9603095D0
(en)
|
1996-02-14 |
1996-04-10 |
Zeneca Ltd |
Quinazoline derivatives
|
|
DE19629652A1
(de)
|
1996-03-06 |
1998-01-29 |
Thomae Gmbh Dr K |
4-Amino-pyrimidin-Derivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
|
|
DE19608588A1
(de)
|
1996-03-06 |
1997-09-11 |
Thomae Gmbh Dr K |
Pyrimido [5,4-d]pyrimidine, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
|
|
EP0888353B1
(de)
|
1996-03-15 |
2003-07-09 |
Novartis AG |
N-7 HETEROCYCLYL-PYRROLO[ 2,3-d]PYRIMIDINE UND IHRE VERWENDUNG
|
|
SK284073B6
(sk)
|
1996-04-12 |
2004-09-08 |
Warner-Lambert Company |
Polycyklické zlúčeniny, ich použitie a farmaceutické kompozície na ich báze
|
|
GB9607729D0
(en)
|
1996-04-13 |
1996-06-19 |
Zeneca Ltd |
Quinazoline derivatives
|
|
WO1997049688A1
(en)
|
1996-06-24 |
1997-12-31 |
Pfizer Inc. |
Phenylamino-substituted tricyclic derivatives for treatment of hyperproliferative diseases
|
|
US6258823B1
(en)
|
1996-07-12 |
2001-07-10 |
Ariad Pharmaceuticals, Inc. |
Materials and method for treating or preventing pathogenic fungal infection
|
|
EP0818442A3
(en)
|
1996-07-12 |
1998-12-30 |
Pfizer Inc. |
Cyclic sulphone derivatives as inhibitors of metalloproteinases and of the production of tumour necrosis factor
|
|
EP0912559B1
(en)
|
1996-07-13 |
2002-11-06 |
Glaxo Group Limited |
Fused heterocyclic compounds as protein tyrosine kinase inhibitors
|
|
HRP970371A2
(en)
|
1996-07-13 |
1998-08-31 |
Kathryn Jane Smith |
Heterocyclic compounds
|
|
DE69718472T2
(de)
|
1996-07-13 |
2003-11-06 |
Glaxo Group Ltd., Greenford |
Bicyclische heteroaromatische verbindungen als protein tyrosine kinase inhibitoren
|
|
KR20000067904A
(ko)
|
1996-07-18 |
2000-11-25 |
디. 제이. 우드, 스피겔 알렌 제이 |
매트릭스 메탈로프로테아제의 포스피네이트계 억제제
|
|
WO1998006842A1
(en)
|
1996-08-16 |
1998-02-19 |
Schering Corporation |
Mammalian cell surface antigens; related reagents
|
|
US6111090A
(en)
|
1996-08-16 |
2000-08-29 |
Schering Corporation |
Mammalian cell surface antigens; related reagents
|
|
WO1998007726A1
(en)
|
1996-08-23 |
1998-02-26 |
Novartis Ag |
Substituted pyrrolopyrimidines and processes for their preparation
|
|
BR9711223A
(pt)
|
1996-08-23 |
1999-08-17 |
Pfizer |
Derivados de cido arilsulfonilamino-hidrox mico
|
|
AU4779897A
(en)
|
1996-10-02 |
1998-04-24 |
Novartis Ag |
Fused pyrazole derivatives and processes for their preparation
|
|
JP4205168B2
(ja)
|
1996-10-02 |
2009-01-07 |
ノバルティス アクチエンゲゼルシヤフト |
ピリミジン誘導体およびその製造法
|
|
ID18494A
(id)
|
1996-10-02 |
1998-04-16 |
Novartis Ag |
Turunan pirazola leburan dan proses pembuatannya
|
|
EP0837063A1
(en)
|
1996-10-17 |
1998-04-22 |
Pfizer Inc. |
4-Aminoquinazoline derivatives
|
|
GB9621757D0
(en)
|
1996-10-18 |
1996-12-11 |
Ciba Geigy Ag |
Phenyl-substituted bicyclic heterocyclyl derivatives and their use
|
|
EP0950059B1
(en)
|
1997-01-06 |
2004-08-04 |
Pfizer Inc. |
Cyclic sulfone derivatives
|
|
IL131042A0
(en)
|
1997-02-03 |
2001-01-28 |
Pfizer Prod Inc |
Arylsulfonylamino hydroxamic acid derivatives
|
|
ES2301194T3
(es)
|
1997-02-05 |
2008-06-16 |
Warner-Lambert Company Llc |
Pirido 2,3-d pirimidinas y 4-aminopirimidinas como inhibidores de la proliferacion celular.
|
|
BR9807824A
(pt)
|
1997-02-07 |
2000-03-08 |
Pfizer |
Derivados de n-hidróxi-beta-sulfonil-propionamida e seu uso como inibidores de metaloproteinases de matriz
|
|
KR20000070923A
(ko)
|
1997-02-11 |
2000-11-25 |
디. 제이. 우드, 스피겔 알렌 제이 |
아릴설포닐 하이드록삼산 유도체
|
|
CO4950519A1
(es)
|
1997-02-13 |
2000-09-01 |
Novartis Ag |
Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
|
|
US6150395A
(en)
|
1997-05-30 |
2000-11-21 |
The Regents Of The University Of California |
Indole-3-carbinol (I3C) derivatives and methods
|
|
US6329375B1
(en)
|
1997-08-05 |
2001-12-11 |
Sugen, Inc. |
Tricyclic quinoxaline derivatives as protein tyrosine kinase inhibitors
|
|
DE69822839T2
(de)
|
1997-08-08 |
2004-08-19 |
Pfizer Products Inc., Groton |
Derivate von aryloxyarylsulfonylamino hydroxyaminsäuren
|
|
WO2000012089A1
(en)
|
1998-08-31 |
2000-03-09 |
Merck & Co., Inc. |
Novel angiogenesis inhibitors
|
|
US6509173B1
(en)
|
1997-10-21 |
2003-01-21 |
Human Genome Sciences, Inc. |
Human tumor necrosis factor receptor-like proteins TR11, TR11SV1, and TR11SV2
|
|
GB9725782D0
(en)
|
1997-12-05 |
1998-02-04 |
Pfizer Ltd |
Therapeutic agents
|
|
GB9800575D0
(en)
|
1998-01-12 |
1998-03-11 |
Glaxo Group Ltd |
Heterocyclic compounds
|
|
GB9800569D0
(en)
|
1998-01-12 |
1998-03-11 |
Glaxo Group Ltd |
Heterocyclic compounds
|
|
GB9801690D0
(en)
|
1998-01-27 |
1998-03-25 |
Pfizer Ltd |
Therapeutic agents
|
|
CA2319236A1
(en)
|
1998-02-09 |
1999-08-12 |
Genentech, Inc. |
Novel tumor necrosis factor receptor homolog and nucleic acids encoding the same
|
|
WO1999045009A1
(en)
|
1998-03-04 |
1999-09-10 |
Bristol-Myers Squibb Company |
Heterocyclo-substituted imidazopyrazine protein tyrosine kinase inhibitors
|
|
PA8469501A1
(es)
|
1998-04-10 |
2000-09-29 |
Pfizer Prod Inc |
Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico
|
|
PA8469401A1
(es)
|
1998-04-10 |
2000-05-24 |
Pfizer Prod Inc |
Derivados biciclicos del acido hidroxamico
|
|
CA2314156C
(en)
|
1998-05-29 |
2010-05-25 |
Sugen, Inc. |
Pyrrole substituted 2-indolinone protein kinase inhibitors
|
|
UA60365C2
(uk)
|
1998-06-04 |
2003-10-15 |
Пфайзер Продактс Інк. |
Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця
|
|
JP2002520324A
(ja)
|
1998-07-10 |
2002-07-09 |
メルク エンド カムパニー インコーポレーテッド |
新規な血管形成インヒビター
|
|
ES2213985T3
(es)
|
1998-11-05 |
2004-09-01 |
Pfizer Products Inc. |
Derivados de hidroxiamida de acido 5-oxo-pirrolidin-2-carboxilico.
|
|
ATE538794T1
(de)
|
1999-01-13 |
2012-01-15 |
Bayer Healthcare Llc |
Gamma carboxyarylsubstituierte diphenylharnstoffverbindungen als p38 kinasehemmer
|
|
EP1165085B1
(en)
|
1999-03-30 |
2006-06-14 |
Novartis AG |
Phthalazine derivatives for treating inflammatory diseases
|
|
GB9912961D0
(en)
|
1999-06-03 |
1999-08-04 |
Pfizer Ltd |
Metalloprotease inhibitors
|
|
ES2262518T5
(es)
|
1999-06-07 |
2009-05-08 |
Immunex Corporation |
Antagonistas de tek.
|
|
US6521424B2
(en)
|
1999-06-07 |
2003-02-18 |
Immunex Corporation |
Recombinant expression of Tek antagonists
|
|
AU6085700A
(en)
|
1999-07-12 |
2001-01-30 |
Genentech Inc. |
Promotion or inhibition of angiogenesis and cardiovascularization by tumor necrosis factor ligand/receptor homologs
|
|
IL147803A0
(en)
|
1999-08-24 |
2002-08-14 |
Ariad Gene Therapeutics Inc |
28-epirapalogs
|
|
EE05330B1
(et)
|
1999-11-05 |
2010-08-16 |
Astrazeneca Ab |
Kinasoliini derivaadid kui VEGF-i inhibiitorid
|
|
ATE514676T1
(de)
|
1999-11-24 |
2011-07-15 |
Sugen Inc |
Ionisierbare indolinon derivate und deren verwendung als ptk liganden
|
|
US6515004B1
(en)
|
1999-12-15 |
2003-02-04 |
Bristol-Myers Squibb Company |
N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases
|
|
US6727225B2
(en)
|
1999-12-20 |
2004-04-27 |
Immunex Corporation |
TWEAK receptor
|
|
US7074408B2
(en)
|
2000-02-25 |
2006-07-11 |
Immunex Corporation |
Use of integrin antagonists to inhibit angiogenesis
|
|
US6630500B2
(en)
|
2000-08-25 |
2003-10-07 |
Cephalon, Inc. |
Selected fused pyrrolocarbazoles
|
|
EP1343782B1
(en)
|
2000-12-21 |
2009-05-06 |
SmithKline Beecham Corporation |
Pyrimidineamines as angiogenesis modulators
|
|
US6995162B2
(en)
|
2001-01-12 |
2006-02-07 |
Amgen Inc. |
Substituted alkylamine derivatives and methods of use
|
|
US7102009B2
(en)
|
2001-01-12 |
2006-09-05 |
Amgen Inc. |
Substituted amine derivatives and methods of use
|
|
US7105682B2
(en)
|
2001-01-12 |
2006-09-12 |
Amgen Inc. |
Substituted amine derivatives and methods of use
|
|
US6878714B2
(en)
|
2001-01-12 |
2005-04-12 |
Amgen Inc. |
Substituted alkylamine derivatives and methods of use
|
|
US20020147198A1
(en)
|
2001-01-12 |
2002-10-10 |
Guoqing Chen |
Substituted arylamine derivatives and methods of use
|
|
US7307088B2
(en)
|
2002-07-09 |
2007-12-11 |
Amgen Inc. |
Substituted anthranilic amide derivatives and methods of use
|
|
TWI329112B
(en)
|
2002-07-19 |
2010-08-21 |
Bristol Myers Squibb Co |
Novel inhibitors of kinases
|
|
NZ543654A
(en)
|
2003-05-23 |
2009-05-31 |
Wyeth Corp |
GITR ligand and GITR ligand-related molecules and antibodies and uses thereof
|
|
WO2005005434A1
(en)
|
2003-07-08 |
2005-01-20 |
Novartis Ag |
Use of rapamycin and rapamycin derivatives for the treatment of bone loss
|
|
EP1660126A1
(en)
|
2003-07-11 |
2006-05-31 |
Schering Corporation |
Agonists or antagonists of the clucocorticoid-induced tumour necrosis factor receptor (gitr) or its ligand for the treatment of immune disorders, infections and cancer
|
|
EP1648900A4
(en)
|
2003-07-11 |
2010-02-10 |
Ariad Pharma Inc |
PHOSPHORUS MACROCYCLES
|
|
TW200523262A
(en)
|
2003-07-29 |
2005-07-16 |
Smithkline Beecham Corp |
Inhibitors of AKT activity
|
|
MXJL06000006A
(es)
|
2003-08-22 |
2006-05-04 |
Avanir Pharmaceuticals |
Derivados de naftiridina sustituidos como inhibidores del factor inhibidor de la migracion de macrofagos y su uso en el tratamiento de enfermedades en el hombre.
|
|
WO2005055808A2
(en)
|
2003-12-02 |
2005-06-23 |
Genzyme Corporation |
Compositions and methods to diagnose and treat lung cancer
|
|
GB0409799D0
(en)
|
2004-04-30 |
2004-06-09 |
Isis Innovation |
Method of generating improved immune response
|
|
US20060002932A1
(en)
|
2004-06-04 |
2006-01-05 |
Duke University |
Methods and compositions for enhancement of immunity by in vivo depletion of immunosuppressive cell activity
|
|
JP4242911B2
(ja)
|
2004-08-26 |
2009-03-25 |
ファイザー・インク |
プロテインキナーゼ阻害薬としてのエナンチオピュアなアミノヘテロアリール化合物
|
|
MX2007004489A
(es)
|
2004-10-13 |
2007-09-21 |
Wyeth Corp |
Analogos de 17-hidroxiwortamina como inhibidores pi3k.
|
|
AU2005295441B2
(en)
|
2004-10-18 |
2009-04-23 |
Amgen, Inc. |
Thiadiazole compounds and methods of use
|
|
ES2657443T3
(es)
|
2005-03-25 |
2018-03-05 |
Gitr, Inc. |
Anticuerpos anti-GITR y usos de los mismos
|
|
CN109485727A
(zh)
|
2005-05-09 |
2019-03-19 |
小野药品工业株式会社 |
程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法
|
|
GB0510390D0
(en)
|
2005-05-20 |
2005-06-29 |
Novartis Ag |
Organic compounds
|
|
MX2008001041A
(es)
|
2005-09-20 |
2008-03-19 |
Pfizer Prod Inc |
Formas farmaceuticas y metodos de tratamiento que usan un inhibidor de la tirosinacinasa.
|
|
WO2007084391A2
(en)
|
2006-01-18 |
2007-07-26 |
Amgen Inc. |
Thiazole compounds as protein kinase b ( pkb) inhibitors
|
|
US20110212086A1
(en)
|
2006-01-19 |
2011-09-01 |
Genzyme Corporation |
GITR Antibodies For The Treatment of Cancer
|
|
AR064155A1
(es)
|
2006-12-07 |
2009-03-18 |
Piramed Ltd |
Compuestos de inhibidores de fosfoinositido-3 quinasa y metodos de uso
|
|
US7705018B2
(en)
|
2007-03-23 |
2010-04-27 |
Amgen Inc. |
Substituted quinolines and their uses in treatment of inflammatory and related conditions
|
|
AU2008231304B2
(en)
|
2007-03-23 |
2011-05-12 |
Amgen Inc. |
Heterocyclic compounds and their uses
|
|
US7919498B2
(en)
|
2007-03-23 |
2011-04-05 |
Amgen Inc. |
Substituted pyrazolo[3,4-d]pyrimidines as PI3K inhibitors
|
|
WO2009005673A1
(en)
*
|
2007-06-28 |
2009-01-08 |
Schering Corporation |
Anti-igf1r
|
|
US8591886B2
(en)
|
2007-07-12 |
2013-11-26 |
Gitr, Inc. |
Combination therapies employing GITR binding molecules
|
|
AU2008276512A1
(en)
|
2007-07-17 |
2009-01-22 |
Amgen Inc. |
Thiadiazole modulators of PKB
|
|
US7897619B2
(en)
|
2007-07-17 |
2011-03-01 |
Amgen Inc. |
Heterocyclic modulators of PKB
|
|
TW200911798A
(en)
|
2007-08-02 |
2009-03-16 |
Amgen Inc |
PI3 kinase modulators and methods of use
|
|
TWI471134B
(zh)
|
2007-09-12 |
2015-02-01 |
Genentech Inc |
肌醇磷脂３－激酶抑制劑化合物及化療劑之組合及使用方法
|
|
CA2701292C
(en)
|
2007-10-25 |
2015-03-24 |
Genentech, Inc. |
Process for making thienopyrimidine compounds
|
|
CA2708157A1
(en)
*
|
2007-12-07 |
2009-06-11 |
Bipar Sciences, Inc. |
Treatment of cancer with combinations of topoisomerase inhibitors and parp inhibitors
|
|
CA2710194C
(en)
|
2007-12-19 |
2014-04-22 |
Amgen Inc. |
Inhibitors of p13 kinase
|
|
US8841312B2
(en)
|
2007-12-19 |
2014-09-23 |
Amgen Inc. |
Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors
|
|
JP5530422B2
(ja)
|
2008-04-07 |
2014-06-25 |
アムジエン・インコーポレーテツド |
細胞周期阻害薬としてのｇｅｍ−二置換およびスピロ環式アミノピリジン／ピリミジン
|
|
US8415376B2
(en)
|
2008-05-30 |
2013-04-09 |
Amgen Inc. |
Inhibitors of PI3 kinase
|
|
US20110177070A1
(en)
|
2008-07-02 |
2011-07-21 |
Emergent Product Development Seatlle, LLC |
TGF-Beta Antagonist Multi-Target Binding Proteins
|
|
WO2010030002A1
(ja)
|
2008-09-12 |
2010-03-18 |
国立大学法人三重大学 |
外来性ｇｉｔｒリガンド発現細胞
|
|
US20110263647A1
(en)
|
2009-01-15 |
2011-10-27 |
Amgen Inc. |
Fluoroisoquinoline substituted thiazole compounds and methods of use
|
|
WO2010096314A1
(en)
|
2009-02-18 |
2010-08-26 |
Amgen Inc. |
INDOLE/BENZIMIDAZOLE COMPOUNDS AS mTOR KINASE INHIBITORS
|
|
MX2011009796A
(es)
|
2009-03-20 |
2011-12-14 |
Amgen Inc |
Inhibidores de la cinasa pi3.
|
|
UY32582A
(es)
|
2009-04-28 |
2010-11-30 |
Amgen Inc |
Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamífero
|
|
EP2430013B1
(en)
|
2009-05-13 |
2014-10-15 |
Amgen Inc. |
Heteroaryl compounds as pikk inhibitors
|
|
MX2011013667A
(es)
|
2009-06-25 |
2012-03-06 |
Amgen Inc |
Compuestos heterociclicos y sus usos.
|
|
WO2010151735A2
(en)
|
2009-06-25 |
2010-12-29 |
Amgen Inc. |
Heterocyclic compounds and their uses
|
|
EA201270013A1
(ru)
|
2009-06-25 |
2012-06-29 |
Амген Инк. |
Гетероциклические соединения и их применение
|
|
WO2010151791A1
(en)
|
2009-06-25 |
2010-12-29 |
Amgen Inc. |
Heterocyclic compounds and their uses
|
|
EP2266984A1
(en)
|
2009-06-26 |
2010-12-29 |
Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts |
Pyrido[2,3-d]pyrimidines as Wnt antagonists for treatment of cancer and arthritis
|
|
CA2772613C
(en)
|
2009-09-03 |
2020-03-10 |
Schering Corporation |
Anti-gitr antibodies
|
|
GB0919054D0
(en)
|
2009-10-30 |
2009-12-16 |
Isis Innovation |
Treatment of obesity
|
|
EP2519544A1
(en)
|
2009-12-29 |
2012-11-07 |
Emergent Product Development Seattle, LLC |
Polypeptide heterodimers and uses thereof
|
|
WO2012142498A2
(en)
|
2011-04-13 |
2012-10-18 |
Innovimmune Biotherapeutics, Inc. |
Mif inhibitors and their uses
|
|
WO2013039954A1
(en)
|
2011-09-14 |
2013-03-21 |
Sanofi |
Anti-gitr antibodies
|
|
US20150087628A1
(en)
|
2012-04-10 |
2015-03-26 |
The Regents Of The University Of California |
Compositions and methods for treating cancer
|
|
US9227978B2
(en)
|
2013-03-15 |
2016-01-05 |
Araxes Pharma Llc |
Covalent inhibitors of Kras G12C
|
|
US9745319B2
(en)
|
2013-03-15 |
2017-08-29 |
Araxes Pharma Llc |
Irreversible covalent inhibitors of the GTPase K-Ras G12C
|
|
AU2014239542A1
(en)
|
2013-03-15 |
2015-10-01 |
Araxes Pharma Llc |
Covalent inhibitors of KRas G12C
|
|
GB201312059D0
(en)
|
2013-07-05 |
2013-08-21 |
Univ Leuven Kath |
Novel GAK modulators
|
|
WO2015054572A1
(en)
|
2013-10-10 |
2015-04-16 |
Araxes Pharma Llc |
Inhibitors of kras g12c
|
|
JO3805B1
(ar)
|
2013-10-10 |
2021-01-31 |
Araxes Pharma Llc |
مثبطات كراس جي12سي
|
|
GB201320729D0
(en)
|
2013-11-25 |
2014-01-08 |
Cancer Rec Tech Ltd |
Therapeutic compounds and their use
|
|
US20170128417A1
(en)
*
|
2014-07-01 |
2017-05-11 |
Vicus Therapeutics, Llc |
Combination drug therapies for cancer and methods of making and using them
|
|
JO3556B1
(ar)
|
2014-09-18 |
2020-07-05 |
Araxes Pharma Llc |
علاجات مدمجة لمعالجة السرطان
|
|
WO2016049565A1
(en)
|
2014-09-25 |
2016-03-31 |
Araxes Pharma Llc |
Compositions and methods for inhibition of ras
|
|
WO2016049568A1
(en)
|
2014-09-25 |
2016-03-31 |
Araxes Pharma Llc |
Methods and compositions for inhibition of ras
|
|
WO2016049524A1
(en)
|
2014-09-25 |
2016-03-31 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
|
EA201792214A1
(ru)
|
2015-04-10 |
2018-01-31 |
Араксис Фарма Ллк |
Соединения замещенного хиназолина
|
|
EP3283462B1
(en)
|
2015-04-15 |
2020-12-02 |
Araxes Pharma LLC |
Fused-tricyclic inhibitors of kras and methods of use thereof
|
|
WO2017015562A1
(en)
|
2015-07-22 |
2017-01-26 |
Araxes Pharma Llc |
Substituted quinazoline compounds and their use as inhibitors of g12c mutant kras, hras and/or nras proteins
|
|
US10647703B2
(en)
|
2015-09-28 |
2020-05-12 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
|
WO2017058792A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
|
US10730867B2
(en)
|
2015-09-28 |
2020-08-04 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
|
EP3356339A1
(en)
|
2015-09-28 |
2018-08-08 |
Araxes Pharma LLC |
Inhibitors of kras g12c mutant proteins
|
|
WO2017058915A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
|
US10858343B2
(en)
|
2015-09-28 |
2020-12-08 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
|
US10875842B2
(en)
|
2015-09-28 |
2020-12-29 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
|
TW201726656A
(zh)
|
2015-11-16 |
2017-08-01 |
亞瑞克西斯製藥公司 |
包含經取代雜環基團之２－經取代喹唑啉化合物及其使用方法
|
|
WO2017100546A1
(en)
|
2015-12-09 |
2017-06-15 |
Araxes Pharma Llc |
Methods for preparation of quinazoline derivatives
|
|
US10822312B2
(en)
|
2016-03-30 |
2020-11-03 |
Araxes Pharma Llc |
Substituted quinazoline compounds and methods of use
|
|
KR102444509B1
(ko)
|
2016-05-18 |
2022-09-19 |
미라티 테라퓨틱스, 인크. |
Kras g12c 억제제
|
|
US10646488B2
(en)
|
2016-07-13 |
2020-05-12 |
Araxes Pharma Llc |
Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
|
|
JP2019529484A
(ja)
|
2016-09-29 |
2019-10-17 |
アラクセス ファーマ エルエルシー |
Ｋｒａｓ ｇ１２ｃ変異体タンパク質の阻害剤
|
|
US10377743B2
(en)
|
2016-10-07 |
2019-08-13 |
Araxes Pharma Llc |
Inhibitors of RAS and methods of use thereof
|
|
EP3558955B1
(en)
|
2016-12-22 |
2021-08-11 |
Amgen Inc. |
Benzisothiazole, isothiazolo[3,4-b]pyridine, quinazoline, phthalazine, pyrido[2,3-d]pyridazine and pyrido[2,3-d]pyrimidine derivatives as kras g12c inhibitors for treating lung, pancreatic or colorectal cancer
|
|
EP3573966A1
(en)
|
2017-01-26 |
2019-12-04 |
Araxes Pharma LLC |
Fused n-heterocyclic compounds and methods of use thereof
|
|
JOP20190272A1
(ar)
|
2017-05-22 |
2019-11-21 |
Amgen Inc |
مثبطات kras g12c وطرق لاستخدامها
|
|
JP2020521740A
(ja)
|
2017-05-25 |
2020-07-27 |
アラクセス ファーマ エルエルシー |
変異体ｋｒａｓ、ｈｒａｓまたはｎｒａｓの調節因子としてのキナゾリン誘導体
|
|
EP3679040B1
(en)
|
2017-09-08 |
2022-08-03 |
Amgen Inc. |
Inhibitors of kras g12c and methods of using the same
|
|
ES2995514T3
(en)
|
2018-05-04 |
2025-02-10 |
Amgen Inc |
Kras g12c inhibitors and methods of using the same
|
|
AU2019262589B2
(en)
|
2018-05-04 |
2022-07-07 |
Amgen Inc. |
KRAS G12C inhibitors and methods of using the same
|
|
MX2020011907A
(es)
|
2018-05-10 |
2021-01-29 |
Amgen Inc |
Inhibidores de kras g12c para el tratamiento de cancer.
|
|
ES2938987T3
(es)
|
2018-06-01 |
2023-04-18 |
Amgen Inc |
Inhibidores de KRAS G12c y métodos de uso de los mismos
|
|
MX2020012204A
(es)
|
2018-06-11 |
2021-03-31 |
Amgen Inc |
Inhibidores de kras g12c para tratar el cáncer.
|
|
CA3100390A1
(en)
|
2018-06-12 |
2020-03-12 |
Amgen Inc. |
Kras g12c inhibitors encompassing piperazine ring and use thereof in the treatment of cancer
|
|
MA52939A
(fr)
|
2018-06-21 |
2021-04-28 |
Janssen Pharmaceutica Nv |
Composés inhibiteurs d'oga
|
|
CN112313212B
(zh)
|
2018-06-21 |
2023-05-05 |
詹森药业有限公司 |
Oga抑制剂化合物
|
|
JP7516029B2
(ja)
|
2018-11-16 |
2024-07-16 |
アムジエン・インコーポレーテツド |
Ｋｒａｓ ｇ１２ｃ阻害剤化合物の重要な中間体の改良合成法
|
|
JP7377679B2
(ja)
|
2018-11-19 |
2023-11-10 |
アムジエン・インコーポレーテツド |
がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法
|
|
WO2020106640A1
(en)
|
2018-11-19 |
2020-05-28 |
Amgen Inc. |
Kras g12c inhibitors and methods of using the same
|
|
EP3738593A1
(en)
|
2019-05-14 |
2020-11-18 |
Amgen, Inc |
Dosing of kras inhibitor for treatment of cancers
|
|
PH12021552922A1
(en)
|
2019-05-21 |
2022-04-04 |
Amgen Inc |
Solid state forms
|
|
US12252486B2
(en)
|
2019-05-21 |
2025-03-18 |
Amgen Inc. |
Solid state forms
|
|
AU2020369569A1
(en)
|
2019-10-24 |
2022-04-14 |
Amgen Inc. |
Pyridopyrimidine derivatives useful as KRAS G12C and KRAS G12D inhibitors in the treatment of cancer
|
|
AR120456A1
(es)
|
2019-11-14 |
2022-02-16 |
Amgen Inc |
Síntesis mejorada del compuesto inhibidor de g12c de kras
|
|
US12466825B2
(en)
|
2019-11-14 |
2025-11-11 |
Amgen Inc. |
Synthesis of KRAS G12C inhibitor compound
|
|
WO2021126816A1
(en)
|
2019-12-16 |
2021-06-24 |
Amgen Inc. |
Dosing regimen of a kras g12c inhibitor
|
|
WO2021236920A1
(en)
|
2020-05-20 |
2021-11-25 |
Teva Pharmaceuticals International Gmbh |
Solid state forms of amg-510 and process for preparation thereof
|